ELISE RICHARD: Open Payments
NPI 1942872460 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,080 in 93 payments from 13 companies in 2025. Trend: 2023 $639 · 2024 $663 · 2025 $2,080
Food & beverage: $2,062Education: $17
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 29 | $509 |
| GENZYME CORPORATION | 12 | $355 |
| Regeneron Healthcare Solutions, Inc. | 10 | $293 |
| AstraZeneca Pharmaceuticals LP | 11 | $223 |
| Verona Pharma, Inc. | 8 | $187 |
| Grifols USA, LLC | 4 | $108 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $100 |
| Amgen Inc. | 3 | $60 |
| Actelion Pharmaceuticals US, Inc. | 2 | $56 |
| Insmed, Inc. | 3 | $55 |
Products named: DUPIXENT, NUCALA, TRELEGY ELLIPTA, Ohtuvayre, FASENRA, TEZSPIRE, Prolastin-C Liquid, OFEV.
Industry payments across LA — which companies pay providers there.
